Legal Representation
Attorney
Joshua G. Gigger
USPTO Deadlines
Next Deadline
157 days remaining
NOA E-Mailed - SOU Required
Due Date
June 02, 2026
Extension Available
Until December 02, 2026
Application History
9 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 2, 2025 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Oct 7, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Oct 7, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Oct 1, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Sep 4, 2025 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Sep 4, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 9, 2025 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Apr 9, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Apr 9, 2025 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
pharmaceutical products for the treatment of central nervous system diseases and disorders; pharmaceutical products for the treatment of vertigo, dizziness, and lightheadedness; pharmaceutical products for the treatment of symptomatic neurogenic orthostatic hypotension; pharmaceutical products for the treatment of symptoms caused by primary autonomic failure, dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy; pharmaceutical products for the treatment of symptoms caused by Parkinson’s disease, multiple system atrophy, and pure autonomic failure
Classification
International Classes
005